ClinicalTrials.gg
CompletedNCT02101112Updated Mar 3, 2016Results posted

Bioavailability of Apixaban Crushed Tablet

A Phase 1 interventional study of Apixaban in Thrombosis, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-03.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing apixaban in Thrombosis — 5 open to participants now, 5 under way, 2 of them phase 3. apixaban · Thrombosis.

Enrollment
10th of 18
69 · median 73
Started
2014
with 1 other
Phase 1
4 of 18
1 open now
Registered
2nd of 18
by date
Lead sponsor
3 of 18
Bristol-Myers Squibb

Among the 18 studies testing apixaban in Thrombosis, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 2nd registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

5 of the 18 studies testing apixaban in Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing apixaban in Thrombosis, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the bioavailability of apixaban crushed tablets suspended in water or mixed with applesauce is similar to the bioavailability of apixaban whole tablets administered orally.

Read the detailed description

This study will investigate the bioavailability of apixaban administered as crushed tablets suspended in water and as crushed tablets mixed with applesauce compared with that of whole tablets. The study results may allow enhancement of the apixaban label to include alternative methods of apixaban administration, which may be of benefit to patients who have difficulty swallowing.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy participants as determined by no deviation from normal in findings of medical history, physical examination, , vital signs, and clinical laboratory tests.
  • Women of allowed. Must be following highly effective methods of

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • History of significant head injury within the last 2 years, including individuals with base of skull fractures
  • Any major surgery within 4 weeks of study drug administration or anticipated within 2 weeks after completion of the study
  • Any gastrointestinal (GI) surgery or GI disease that could impact absorption of study drug
  • History of Gilbert's Syndrome
  • Inability to tolerate oral medication
  • Inability to be venipunctured and/or tolerate venous access
  • Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study drug administration
  • Any laboratory test results outside of the range of normal, confirmed by repeat results of:

    • count \<150,000 cells/µL
    • > (ULN)
    • International normalized ratio >ULN
    • >ULN
    • Aspartate aminotransferase >ULN
    • Total >ULN
    • Serum creatinine ≥1.5 mg/dL
    • \<lower limit of normal (LLN)
    • Hematocrit \<LLN
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Apixaban, 10 mg (whole tablets)

    Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)

    Drug: Apixaban

  • Experimental
    Apixaban, 10 mg (crushed and suspended in water)

    Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water

    Drug: Apixaban

  • Experimental
    Apixaban, 10 mg (crushed and mixed with applesauce)

    Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce

    Drug: Apixaban

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban

    Maximum observed plasma concentration (Cmax) measured in nanograms per milliliter (ng/mL)

    Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60 and 72 hours post dose

  2. Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban

    Area Under the Plasma Concentration-time Curve (AUC) From Time of Zero Extrapolated to Infinite Time (INF) \[AUC (INF)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)

    Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose

  3. Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

    Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Concentration \[AUC (0-T)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)

    Time frame: Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose

Secondary outcomes

  1. Number of Participants With Serious Adverse Events, Death, or Discontinuation Due to Adverse Events by Study Completion

    Adverse Event (AE) = any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious Adverse Event (SAE)= a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Randomization to May 2014; approximately 6 weeks

  2. Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban

    Time of maximum observed plasma concentration (Tmax) measured in hours (h)

    Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose

  3. Terminal Plasma Half-life (T-HALF) of Apixaban

    Terminal plasma half-life (T-HALF) was derived from plasma concentration versus time data. T-HALF was the time required for one half of the total amount of administered drug to be eliminated from the body.

    Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose

  4. Relative Bioavailability (Frel) of Apixaban

    Frel is calculated using the treatment ratio of AUC(INF) where the denominator is the AUC(INF) of the reference therapy, 10mg of Apixaban (whole tablet).

    Time frame: Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose

07

Results

Posted Mar 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneTreatment A Then Treatment B Then Treatment CTreatment A Then Treatment C Then Treatment BTreatment B Then Treatment C Then Treatment ATreatment B Then Treatment A Then Treatment CTreatment C Then Treatment A Then Treatment BTreatment C Then Treatment B Then Treatment A
Started656565
Completed655555
Not completed001010
Withdrew: Adverse event001000
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryAdjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban

Maximum observed plasma concentration (Cmax) measured in nanograms per milliliter (ng/mL)

Time frame:
Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60 and 72 hours post dose
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban
ng/mLApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Adjusted Geometric Mean of Maximum Observed Plasma Concentration (Cmax) of Apixaban236 (217 to 256)249 (232 to 266)186 (174 to 199)
Statistical analysis
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Suspended in Water) · Ratio of adjusted geometric means: 1.054 · 90% CI 0.994 to 1.118
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Mixed With Applesauce) · Ratio of adjusted geometric means: 0.788 · 90% CI 0.741 to 0.839
PrimaryAdjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban

Area Under the Plasma Concentration-time Curve (AUC) From Time of Zero Extrapolated to Infinite Time (INF) \[AUC (INF)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)

Time frame:
Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban
ng*h/mLApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinite Time [AUC(INF)] of Apixaban2461 (2273 to 2664)2528 (2375 to 2692)2055 (1915 to 2206)
Statistical analysis
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Suspended in Water) · Ratio of adjusted geometric means: 1.027 · 90% CI 0.981 to 1.076
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Mixed With Applesauce) · Ratio of adjusted geometric means: 0.835 · 90% CI 0.797 to 0.875
PrimaryAdjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Quantifiable Concentration \[AUC (0-T)\] is measured as nanograms multiplied by hours per milliliter (ng\*h/mL)

Time frame:
Days 1, 5, and 9 predose and 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 hours post dose
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban
ng*h/mLApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Adjusted Geometric Mean of Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-T)] of Apixaban2423 (2238 to 2623)2488 (2336 to 2651)2015 (1876 to 2165)
Statistical analysis
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Suspended in Water) · Ratio of adjusted geometric means: 1.027 · 90% CI 0.981 to 1.075
  • Apixaban, 10 mg (Whole Tablets) vs Apixaban, 10 mg (Crushed and Mixed With Applesauce) · Ratio of adjusted geometric means: 0.832 · 90% CI 0.794 to 0.871
SecondaryNumber of Participants With Serious Adverse Events, Death, or Discontinuation Due to Adverse Events by Study Completion

Adverse Event (AE) = any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious Adverse Event (SAE)= a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Randomization to May 2014; approximately 6 weeks
Reported as:
Number · participants
Number of Participants With Serious Adverse Events, Death, or Discontinuation Due to Adverse Events by Study Completion
participantsApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Deaths000
SAEs000
Drug-related AEs010
Discontinuation due to AE010
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) of Apixaban

Time of maximum observed plasma concentration (Tmax) measured in hours (h)

Time frame:
Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
Reported as:
Median · hours
Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
hoursApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban2.00 (1.00 to 5.00)2.00 (0.583 to 4.00)2.00 (1.00 to 4.00)
SecondaryTerminal Plasma Half-life (T-HALF) of Apixaban

Terminal plasma half-life (T-HALF) was derived from plasma concentration versus time data. T-HALF was the time required for one half of the total amount of administered drug to be eliminated from the body.

Time frame:
Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
Reported as:
Mean · hours
Terminal Plasma Half-life (T-HALF) of Apixaban
hoursApixaban, 10 mg (Whole Tablets)Apixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Terminal Plasma Half-life (T-HALF) of Apixaban12.4 ± 5.3912.2 ± 5.1912.5 ± 5.05
SecondaryRelative Bioavailability (Frel) of Apixaban

Frel is calculated using the treatment ratio of AUC(INF) where the denominator is the AUC(INF) of the reference therapy, 10mg of Apixaban (whole tablet).

Time frame:
Days 1, 5 and 9 pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 9, 12 24, 36, 48, 60 and 72 hrs post dose
Reported as:
Geometric mean · ratio
Relative Bioavailability (Frel) of Apixaban
ratioApixaban, 10 mg (Crushed and Suspended in Water)Apixaban, 10 mg (Crushed and Mixed With Applesauce)
Relative Bioavailability (Frel) of Apixaban1.03 ± 240.836 ± 20

Adverse events

Collected over Day 1 to May 2014; approximately 6 weeks F. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban, 10 mg (Whole Tablets)—0/32 (0%)0/32 (0%)
Apixaban, 10 mg (Crushed and Suspended in Water)—0/33 (0%)0/33 (0%)
Apixaban, 10 mg (Crushed and Mixed With Applesauce)—0/32 (0%)0/32 (0%)

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Apixaban, 10 mg (Whole Tablets)
Mean32.3 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban, 10 mg (Whole Tablets)
Female7
Male26
Weight
Weight(kilograms)Apixaban, 10 mg (Whole Tablets)
Mean77.40 ± 7.933
Height
Height(centimeters)Apixaban, 10 mg (Whole Tablets)
Mean172.13 ± 8.322
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter^2)Apixaban, 10 mg (Whole Tablets)
Mean26.14 ± 2.166
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Song Y, Chang M, Suzuki A, Frost RJ, Kelly A, LaCreta F, Frost C. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Clin Ther. 2016 Jul;38(7):1674-1685.e1. doi: 10.1016/j.clinthera.2016.05.004. Epub 2016 Jun 10. PubMed 27292282 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2014
First posted
Apr 1, 2014
Start
Mar 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Mar 3, 2016
Last update
Mar 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02101112
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Mar 2014
Primary completion
May 2014
Completion
May 2014
Results posted
Mar 3, 2016
Last update
Mar 3, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion